Drug Profile
DRF 7295
Alternative Names: DRF7295Latest Information Update: 02 Oct 2015
Price :
$50
*
At a glance
- Originator Dabur Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer
Most Recent Events
- 20 Apr 2008 Dabur Pharma has been acquired by Fresenius Kabi
- 18 May 2007 Phase II development is ongoing
- 31 Oct 2005 Phase-II clinical trials in Breast cancer in India (Parenteral)